|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Multivariate model analysis, including T2D status, age, and body mass index (BMI), displayed significant covariance in PPARGC-1α rs8192678; SIRT1 rs7896005; TCF7L2 rs7903146 and rs122243326; UCP3 rs3781907; and HHEX rs1111875 with a P < 0.05.
|
31759989 |
2020 |
|
PPARGC1A
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
HG-HF significantly depressed expression of PGC-1α (peroxisome proliferator-activated receptor-γ coactivator-1α) and OPA1 (optic atrophy 1) by reducing [Ca<sup>2+</sup>]<sub>i</sub>, whereas OPA1 supplementation partly reversed those detrimental effects induced by TRPV1<sup>-/-</sup> Furthermore, capsaicin treatment not only attenuated CMECs injury induced by HG-HF but also mitigated cardiac microvascular injury induced by T2DM.
|
29735636 |
2018 |
|
PPARGC1A
|
0.600 |
Biomarker
|
disease |
BEFREE |
An interaction between ERRα and peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) has also recently been shown to regulate an enzyme in the β-oxidation of free fatty acids, thereby suggesting that ERRα plays an important role in obesity and type 2 diabetes.
|
29216352 |
2018 |
|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The impact of six polymorphisms of PGC-1α with Type 2 Diabetes (T2D) susceptibility was evaluated on 1125 samples comprising of 554 T2D cases and 571 controls among three endogamous groups (Bania, Brahmin and Jat Sikh) of North-West India (Punjab).
|
29063962 |
2018 |
|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A single nucleotide variant of the PPARGC1A gene (rs8192678) is associated with T2D susceptibility, relative risk of obesity and insulin resistance, and lower indices of β cell function.
|
29186342 |
2018 |
|
PPARGC1A
|
0.600 |
Biomarker
|
disease |
BEFREE |
We hypothesized that targeting PGC-1α acetylation in the liver, a chemical modification known to inhibit hepatic gluconeogenesis, could be potentially used for treatment of T2D.
|
28340340 |
2017 |
|
PPARGC1A
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Melatonin supplementation in combination with exercise behavior may ameliorate IR, hypertension and exercise performance or fatigue possibly by improving antioxidative activities, hyperlipidemia, inflammatory cytokines via up-regulation of GLUT4, PGC-1 α and mitochondrial biogenesis in T2DM rats.
|
28578257 |
2017 |
|
PPARGC1A
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the anti-diabetic effect of PPD and PPT appeared to be partially mediated by the suppression of hepatic metabolism genes expression such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha, phosphoenolpyruvate carboxykinase, and glucose-6-phosphatase, as well as facilitating lipid metabolism genes expression such as microsomal TG transfer protein in the liver tissues of T2DM mice.
|
28824430 |
2017 |
|
PPARGC1A
|
0.600 |
Biomarker
|
disease |
BEFREE |
Histological results confirmed that renal expression of key proteins was reduced in DKD patients with respect to mitochondrial biogenesis (PGC-1α, p-AMPK) and FA oxidation (PPAR-α, CPT-1) as compared to that in the control and T2DM groups.
|
28956034 |
2017 |
|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thermogenic genes expressions in epicardial adipose tissue (UCP1: OR 0.617, 95%CI 0.103-0.989, p=0.042; PGC1α: OR 0.416, 95%CI 0.171-0.912, p=0.031; PRDM16: OR 0.643, 95%CI 0.116-0.997, p=0.044) were showed as protective factors against the presence of heart failure with reduced left ventricular ejection fraction, and age (OR 1.643, 95%CI 1.001-3.143, p=0.026), presence of coronary artery disease (OR 6.743, 95%CI 1.932-15.301, p<0.001) and type-2-diabetes mellitus (OR 4.031, 95%CI 1.099-7.231, p<0.001) were associated as risk factors.
|
28824327 |
2017 |
|
PPARGC1A
|
0.600 |
Biomarker
|
disease |
BEFREE |
The energy homeostasis is regulated by a network consisting of "fuel gauze" called AMP-activated protein kinase (AMPK), the NAD<sup>+</sup> dependent type III deacetylase (SIRT1) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) which is disrupted in T2D.
|
28751004 |
2017 |
|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Haplotype comparison analysis indicated that CTTCGGG and CTCTGGG haplotypes with the order of PPARG rs1801282 C>G, PPARG rs3856806 C>T, PPARGC1A rs8192678 C>T, PPARGC1A rs2970847 C>T, PPARGC1A rs3736265 G>A, PPARGC1B rs7732671 G>C and PPARGC1B rs17572019 G>A polymorphisms in gene position significantly increased the risk of T2DM.
|
28418876 |
2017 |
|
PPARGC1A
|
0.600 |
Biomarker
|
disease |
BEFREE |
A haplotype-based gene-gene interaction was observed significantly (U = -6.28, P < .001), indicating the possibility of an interaction between haplotype AAG of the PPARGC1A gene and haplotypes CTCG (odds ratio [OR] = 1.745, 95% confidence interval [95% CI] 1.069-2.847) and CTCA (OR = 0.239, 95% CI 0.060-0.958) of the UCP1 gene.Haplotype-based interaction between the PPARGC1A and UCP1 genes is associated with IFG or T2DM among residents in Henan, China.
|
28591028 |
2017 |
|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Associations of PGC-1α variants rs10517030 and rs10212638 with T2DM were analyzed in a dominant genetic model, and were tested for interactions of genotypes and nutrients with T2DM risk.
|
28488691 |
2017 |
|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The significant associations between PGC-1α polymorphisms and T2DM are also discussed in this review.
|
27094040 |
2016 |
|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In a large sample of the Caucasians the rs8192673 of the PGC-1α gene and the rs1801282 of the PPAR-γ gene were associated with waist circumference in subjects with T2DM.
|
25928419 |
2015 |
|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The rs2454206" genes_norm="54790">p.Ile1762Val substitution (TET2-rs2454206) was associated with liver PPARGC1A-methylation and transcriptional levels, and Type 2 diabetes.Our results suggest that 5-hmC might be involved in the pathogenesis of NAFLD by regulating liver mitochondrial biogenesis and PPARGC1A expression.
|
26356709 |
2015 |
|
PPARGC1A
|
0.600 |
Biomarker
|
disease |
BEFREE |
Previous studies by our group have also demonstrated the role of PGC-1α in the fetal origins of T2D.
|
25753246 |
2015 |
|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to explore the possible associations among polymorphisms Gly482Ser, Thr394Thr and Thr528Thr of the PGC-1alpha gene and the risk of type 2 diabetes in Kurdish-Iranians.
|
25282005 |
2015 |
|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The trends observed for genetic association of PPARGC1A SNPs, rs4235308, and rs7656250 for T2D between Haitian Americans and African Americans point out differences in Black race and warrant replicative study with larger sample size.
|
25977930 |
2015 |
|
PPARGC1A
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, our research pinpoints the role of several new T2D-associated genes (such as Srebf1 and Ppargc1) in the human population.
|
25758573 |
2014 |
|
PPARGC1A
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in the peroxisome proliferator-activated receptor (PPAR) and peroxisome proliferator-activated receptor gamma co-activator 1 (PGC1) gene families and type 2 diabetes.
|
24359475 |
2014 |
|
PPARGC1A
|
0.600 |
Biomarker
|
disease |
BEFREE |
The effect of exercise on epigenetic modifications of PGC1: The impact on type 2 diabetes.
|
24703492 |
2014 |
|
PPARGC1A
|
0.600 |
Biomarker
|
disease |
BEFREE |
PGC-1α plays a central role in hepatic gluconeogenesis and has been implicated in the onset of type 2 diabetes.
|
25497092 |
2014 |
|
PPARGC1A
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to investigate DNA promoter methylation and gene expression of PPARGC1A in skeletal muscle from first degree relatives (FDR) of T2D patients, and to determine the association with insulin action as well as the influence of family relation.
|
23505498 |
2013 |